Amoy Diagnostics Co Ltd
300685
Company Profile
Business description
Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.
Contact
39 Dingshan Road
Haicang District
Xiamen361027
CHNT: +86 5926806835
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
1,144
Stocks News & Analysis
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
stocks
Could merger breathe new life into struggling ASX asset manager?
Platinum’s board voted unanimously in favour of a merger we expect would be value accretive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,815.30 | 5.00 | -0.06% |
CAC 40 | 7,808.17 | 21.12 | -0.27% |
DAX 40 | 24,160.64 | 94.67 | -0.39% |
Dow JONES (US) | 44,392.41 | 20.90 | 0.05% |
FTSE 100 | 8,998.06 | 56.94 | 0.64% |
HKSE | 24,203.32 | 63.75 | 0.26% |
NASDAQ | 20,638.02 | 52.49 | 0.26% |
Nikkei 225 | 39,459.62 | 110.06 | -0.28% |
NZX 50 Index | 12,678.69 | 7.99 | -0.06% |
S&P 500 | 6,264.36 | 4.61 | 0.07% |
S&P/ASX 200 | 8,570.40 | 9.70 | -0.11% |
SSE Composite Index | 3,519.65 | 9.47 | 0.27% |